Shots:

• The US FDA has accepted resubmission of BLA- seeking accelerated approval of sacituzumab govitecan to treat patients with mTNBC- prior treated with at least two therapies for metastatic disease- as a complete class 2 response
• The company is closely working with the US FDA to facilitate its review on BLA- which allow the company to bring potentially transformational therapy targeting unmet medical needs of mTNBC patients
• Sacituzumab govitecan is a first-in-class ADC delivering SN-38 to tumor cells by targeting the Trop-2 antigen and has received FDA’s FT & BT designation with its expected PDUFA date as June 02- 2020

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: GlobeNewswire